ADVOCATE. CONNECT. INNOVATE.

Science First: Breaking Barriers in Parkinson’s Disease

San Diego,CA

6/7/2018

10:00am - 1:00pm

Neurological disorders are a leading cause of disability around the globe, the fastest growing of which is Parkinson’s disease. The most significant underlying risk factor in the development of Parkinson’s is age, and as our aging population continues to grow at a rapid pace this debilitating disease will only become more of a burden on our society. What are the latest developments in the space and how close are we to a breakthrough solution?

Today, we know that Parkinson’s is caused by a combination of genetic and environmental factors, but the details of the causes and how to effectively slow progression of the disease remain unsolved. Johnson & Johnson Innovation, JLABS and Janssen R&D are bringing together experts and innovators in the field to share their new discoveries, research and solutions for Parkinson’s disease. You’ll hear a series of presentations on cutting-edge science, followed by an interactive panel discussion around the current state of the market, trends around new innovations, regulatory and other development hurdles and a look towards what we can expect in the short-term.

Speakers:
David Bredt, Ph.D | Global Head of Discovery, Neuroscience, Janssen R&D read bio»
John Forsayeth | Professor Emeritus, Department of Neurological Surgery, Parkinson’s Disease Clinic and Research Center, UCSF read bio»
Nicholas Hertz | Chief Scientific Officer, Mitokinin read bio»
Bill Martin, Ph.D | CSO, BlackThorn Therapeutics read bio»
[Moderator] Stuart Perry, Ph.D | Sr. Scientist, Antibody Discovery, Janssen R&D read bio»
Dianna Price | Senior Director of Neurosciences, Neuropore read bio»

Agenda:
10:00am | Registration and networking
10:20am | Introduction
10:25am | Presentations
11:20am I Panel Discussion and Q&A
12:00pm I Networking Lunch
1:00pm I Program Close


Fees:
$35 | General Public
$25 | Student
$45 | At the Door

Location:
JLABS in San Diego
3210 Merryfield Row
San Diego, CA


Speakers' Biographies:
David Bredt, M.D., Ph.D | Global Head of Discovery, Neuroscience, Janssen R&D
David is the Site Leader for Janssen’s R&D facility in La Jolla. In this role, he oversees preclinical biology and chemistry research as well as leads the biomarker and pharmacogenomics programs that support Johnson and Johnson’s neuroscience franchise. His previous industry experience was with Eli Lilly and Company (2004-2011) where he was Vice President of Integrative Biology and Vice President of Neuroscience Research. In these roles, Bredt’s organizations have discovered numerous molecular candidates that are being studied as novel clinical therapies for pain, migraine, neurodegenerative, and neuropsychiatric disorders. Connect with David: Connect on LinkedIn



John Forsayeth | Professor Emeritus, Department of Neurological Surgery, Parkinson’s Disease Clinic and Research Center, UCSF
John Forsayeth is currently Professor Emeritus of Neurological Surgery at the University of California San Francisco (UCSF). He received his Ph.D. in Biochemistry from Monash University, Australia, in 1984 and subsequently did two post-doctoral fellowships at UCSF in the Department of Physiology. In 1989, he moved to the UCSF Department of Anesthesia to start his own laboratory where he was promoted to Assistant Professor. In 1997, he was appointed Director of Molecular Biology at Neurex Corporation in Menlo Park, CA. The Company was subsequently acquired by Elan Inc. At Elan, he was promoted to Principal Scientist and asked to establish a Parkinson’s disease research team. In 2001, he moved to Avigen Inc., Alameda, CA, to become Director of Neurobiology. In 2004, he returned to UCSF to join the laboratory of Dr. Krystof Bankiewicz and, in 2009, was promoted to Adjunct Professor. He is the founder of two biotechnology Companies, Xalud Therapeutics and Rio Pharmaceuticals, where he serves as Chief Scientific Officer at both. Connect with John: Connect on LinkedIn



Nicholas Hertz | Chief Scientific Officer, Mitokinin
Nicholas T Hertz, Ph.D. is Chief Scientific Officer at Mitokinin Inc, a biopharmaceutical company focused on developing PINK1-targeted small molecules to treat neurodegenerative disease. As the founding CSO of Mitokinin, Nicholas helped to establish the Company's scientific and strategic vision and led the seed and Series A financings. He is a widely published neuroscientist and chemical biologist, with 15 lead or co-author publications in top-tier journals including Cell, Nature, Neuron and Nature Genetics. Following a UCLA Biochemistry BS (Magna Cum Laude) Nicholas earned his Ph.D. in Chemical Biology working in the Shokat Lab at UCSF and completed a postdoctoral fellowship in the lab of Marc Tessier-Lavigne at Rockefeller University and Stanford University. Connect with Nick: Connect on LinkedIn



William J. Martin, Ph.D | Chief Scientific Officer, BlackThorn Therapeutics
William J. Martin, PhD is Chief Scientific Officer at BlackThorn Therapeutics, a biopharmaceutical company focused on creating new medicines for mental health disorders. As a founding team member of BlackThorn, he established the company’s scientific vision and raised venture capital funding through Series A. A systems neuroscientist by training, Bill began his industrial career at Merck where he had research, development and strategic responsibilities in Neuroscience. Bill served as a member on the committee that oversaw the strategic direction of the Merck’s Neuroscience franchise as well as a co-chair for Clinical Development teams for CNS drug candidates. Bill continued his career at Theravance Biopharma where he had discovery and clinical development responsibilities, led the company’s research portfolio planning initiative and was a member of the licensing and strategic partnership team. Bill remains an active member of the scientific community at-large. A co-author on more than 70 primary research and review articles, he is chair of the Government and Public Affairs committee and former Councilor of the Society for Neuroscience. Bill graduated from Swarthmore College, earned his PhD from Brown University and carried out his postdoctoral research at the Keck Center for Integrative Neuroscience at the University of California at San Francisco. Connect with Bill: Connect on LinkedIn



[Moderator] Stuart Perry, Ph.D | Senior Scientist of Antibody Discovery, Janssen R&D
As part of the World Without Disease Accelerator, Stuart is a Senior Scientist in the La Jolla group focused on therapeutic platforms. He came to Janssen 7 years ago as part of the Crucell team investigating infectious disease targets, and has since transitioned into leading the antibody discovery efforts for neurodegenerative disease. Stuart has a background in molecular virology, which includes work in a viral-based gene therapy program at Schering Plough. Prior to Janssen, Stuart completed a postdoctoral fellowship at the La Jolla Institute for Allergy and Immunology and holds a PhD in Cellular & Molecular Biology from the University of Wisconsin. Connect with Stuart: Connect on LinkedIn


Diana Price, Ph.D | Sr. Director, Neurosciences, Neuropore
Dr. Price is the Senior Director of Neurosciences and In Vivo Pharmacology at Neuropore Therapies where she has lead research efforts supporting drug discovery, preclinical development, and translational biomarker studies since 2011. Dr. Price received her doctorate in Neurosciences from the UCSD School of Medicine in 2000. She conducted a postdoctoral appointment from 2000-2003, and then transitioned to an academic research faculty member at the National Center for Microscopy and Imaging Research at UCSD while conducting collaborative multi-scale imaging, behavioral pharmacology and bioinformatics research in pursuit of characterizing translational models of CNS disorders. Dr. Price moved to industry in 2007, with a position at ACADIA Pharmaceuticals as a member of the drug-discovery team for neurological and psychiatric disorders utilizing behavioral pharmacology and neuroanatomical techniques to evaluate drug candidates and provide proof of concept data for preclinical development. Connect with Diana: Connect on LinkedIn

Click Here for More Information

Contact: Michelle Maiello
Contact Email: mmaiello@ITS.JNJ.com

Event Address:

JLABS in San Diego
3210 Merryfield Row
San Diego, CA